Tag Archives: GLP-1 therapy

Why does clinical inertia diabetes continue to slow progress, even when better treatments are widely available? It is a bit like having a high-performance car but hesitating to press the accelerator. Despite major advances in medications and care models, delays in intensifying therapy remain common. As a result, many patients …

GLP-1 dose escalation is becoming a critical topic as demand for these therapies continues to surge. From semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro), these medications are reshaping diabetes and weight management. However, are clinicians and patients moving faster than the evidence supports? As real-world practices evolve, dosing strategies often stray …

As the use of GLP-1 receptor agonists expands, clinicians increasingly face a key challenge: how do you manage patients with multimorbidity using GLP-1 therapies? These treatments are no longer limited to glycemic control. Instead, they now play a central role in cardiovascular protection, weight management, and even renal outcomes. However, …

As GLP-1 therapies become a long-term cornerstone in diabetes care, monitoring patients on these treatments is gaining renewed attention. Clinicians once focused mainly on A1C and weight, but is that enough today? Much like checking only the speed of a car without looking at fuel or engine health, relying on …

Have you ever wondered why weight seems to come back so quickly after stopping a medication that once worked so well? Weight regain after GLP-1 therapy has become a growing concern as more patients discontinue treatments like semaglutide or liraglutide. While these medications are highly effective for weight loss and …

As GLP-1 receptor agonists become more common in diabetes and weight management, new concerns are emerging around how GLP-1 medications are managed before surgery. What happens when a medication that slows digestion meets anesthesia? Increasingly, clinicians are asking whether continuing these therapies before surgery could raise aspiration risk. Clear protocols …

Early onset type 2 diabetes is no longer rare, and its rise among younger adults raises serious concerns. What happens when a chronic condition that typically appears later in life begins decades earlier? Much like starting a marathon with added weight, younger patients face a longer disease course and a …

Staying consistent with GLP-1 therapy remains one of the biggest challenges in diabetes management today. While these therapies offer strong glycemic control, meaningful weight loss, and even cardiovascular benefits, many patients stop treatment earlier than expected. Why does that happen, and what can clinicians do differently? In many ways, GLP-1 …

Researchers are beginning to explore how GLP-1 therapies may influence sleep, recovery, and overall metabolic health. Could a medication designed for blood sugar control also help patients sleep better? As surprising as it sounds, emerging evidence suggests a meaningful connection. This article looks at how GLP-1 receptor agonists may indirectly …

GLP-1 receptor agonists have reshaped the management of type 2 diabetes and obesity. However, growing interest now surrounds the potential role of GLP-1 therapy in normal-weight patients with cardiometabolic risk and whether treatment decisions should rely less on BMI alone. While body mass index remains a widely used screening tool, …